| Name | Title | Contact Details |
|---|
The Private Diagnostic Clinic (PDC) is the physician practice of Duke Health. It is one of the first and the largest academic multi-specialty group practices in the United States. The PDC is a member-led organization more than 1,600 members, and is governed by a Board of Managers. As a professional limited liability company (PLLC), the PDC owns and operates primary care and specialty care clinics in central and eastern North Carolina, as well as the Triad. Through a diverse and integrated network of providers, patients have convenient, accessible and high quality primary and specialty care close to home. In addition to patient care, PDC members conduct cutting-edge research and train the future health care workforce as faculty in the Duke University School of Medicine. The PDC collaborates with other entities within the Duke University Health System to expand opportunities and advance Duke`s clinical, research and academic missions.
Assil Eye Institute is a Santa Monica, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.
Campanile Plastic Surgery is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Queens-Long Island Medical Group, P.C. is a Garden City, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.